文献速递前列腺癌

医师健康研究中定期使用阿司匹林与致死性前列腺癌风险的关系

Regular Aspirin Use and the Risk of Lethal Prostate Cancer in the Physicians' Health Study.
PubMed 文献 · Eur Urol · 2017-02-08

基于医师健康研究22 071名健康男性医师的前瞻性队列,评估定期使用阿司匹林(每周超过3片)与致死性前列腺癌风险及诊断后生存的关系。结果显示当前和既往定期使用阿司匹林与致死性前列腺癌风险降低相关,诊断后当前使用与致死性前列腺癌风险和全因死亡风险降低相关。

要点

  • 当前定期使用阿司匹林者致死性前列腺癌风险低于从不使用者(HR 0.68,95%CI 0.52-0.89)。
  • 既往定期使用阿司匹林者致死性前列腺癌风险低于从不使用者(HR 0.54,95%CI 0.40-0.74)。
  • 诊断后当前使用阿司匹林与致死性前列腺癌风险(HR 0.68,95%CI 0.52-0.90)和全因死亡风险(HR 0.72,95%CI 0.61-0.9)降低相关。

核心结论

  • 在所有参与者中,当前定期使用阿司匹林与致死性前列腺癌风险降低相关。
  • 诊断后当前使用阿司匹林与诊断后生存改善相关,与阿司匹林对前列腺癌进展的潜在抑制作用一致。
  • 作者认为需要随机试验来证实或反驳这些发现。

研究设计与样本

  • 1981/82年,医师健康研究将22 071名健康男性医师随机分配至阿司匹林、β-胡萝卜素、两者联合或安慰剂组。
  • 试验于1988年结束后,通过年度问卷收集截至2009年全队列的阿司匹林使用、癌症诊断和结局数据,以及截至2015年前列腺癌患者的数据。
  • 采用Cox比例风险模型估计全队列致死性前列腺癌风险及最初诊断为非致死性前列腺癌男性的诊断后生存风险比(HR)。

主要发现

  • 截至2009年,502名男性发生致死性前列腺癌。
  • 与从不使用者相比,当前定期使用阿司匹林者致死性前列腺癌风险HR 0.68(95%CI 0.52-0.89),既往定期使用者HR 0.54(95%CI 0.40-0.74)。
  • 在生存分析中,3277名诊断为非致死性前列腺癌的男性中有407名截至2015年发生致死性疾病。
  • 诊断后当前使用阿司匹林与致死性前列腺癌风险降低相关(HR 0.68,95%CI 0.52-0.90),与全因死亡风险降低相关(HR 0.72,95%CI 0.61-0.9)。

关键数值与推荐

  • 定期使用阿司匹林定义为每周超过3片。
  • 致死性前列腺癌定义为转移或前列腺癌死亡。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 无法评估阿司匹林剂量。
  • 部分敏感性分析中观察到不一致性。
  • 作者认为需要随机试验来证实或反驳这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Regular aspirin use probably protects against some malignancies including prostate cancer (PC), but its impact on lethal PC is particularly unclear. OBJECTIVE: To investigate the association between regular aspirin and (1) the risk of lethal PC in a large prospective cohort and (2) survival after PC diagnosis. DESIGN, SETTING, AND PARTICIPANTS: In 1981/82, the Physicians' Health Study randomized 22 071 healthy male physicians to aspirin, β-carotene, both, or placebo. After the trial ended in 1988, annual questionnaires have obtained data on aspirin use, cancer diagnoses, and outcomes up to 2009 for the whole cohort, and to 2015 for PC patients. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We evaluated the relationship between regular aspirin (>3 tablets/week) and lethal PC (metastases or PC death). Cox proportional-hazards models estimated hazard ratios (HRs) for the risk of lethal PC in the whole cohort and postdiagnosis survival among men initially diagnosed with nonlethal PC. RESULTS AND LIMITATIONS: Risk analysis revealed that 502 men developed lethal PC by 2009. Current and past regular aspirin was associated with a lower risk of lethal PC (current: HR 0.68, 95% confidence interval [CI] 0.52-0.89; past: HR 0.54, 95% CI 0.40-0.74) compared to never users. In the survival analysis, 407/3277 men diagnosed with nonlethal PC developed lethal disease by 2015. Current postdiagnostic aspirin was associated with lower risks of lethal PC (HR 0.68, 95% CI 0.52-0.90) and overall mortality (HR 0.72, 95% CI 0.61-0.9). We could not assess aspirin dose, and inconsistencies were observed in some sensitivity analyses. CONCLUSIONS: Current regular aspirin use was associated with a lower risk of lethal PC among all participants. Current postdiagnostic use was associated with improved survival after diagnosis, consistent with a potential inhibitory effect of aspirin on PC progression. A randomized trial is warranted to confirm or refute these findings. PATIENT SUMMARY: We examined the potential effect of regular aspirin use on lethal prostate cancer. We found that taking aspirin was associated with a lower risk of lethal prostate cancer, and taking it after diagnosis may help to prevent prostate cancer from becoming fatal.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Downer MK, Allard CB, Preston MA, et al. Regular Aspirin Use and the Risk of Lethal Prostate Cancer in the Physicians' Health Study. Eur Urol. 2017. PMID: 28189429. doi:10.1016/j.eururo.2017.01.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。